Preliminary Q1 2026 results

Committed to solid profitable growth

April 27, 2026

Forward looking and intended use statements

Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises, and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Regulation G: In this presentation, QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, and other non-U.S. GAAP figures (generally accepted accounting principles), to provide additional insight on performance. Adjusted results include adjusted net sales, adjusted gross income, adjusted net income, adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted operating income margin, adjusted net income before taxes, adjusted income tax, adjusted tax rate, adjusted EBITDA, adjusted EPS, adjusted diluted EPS and free cash flow. Adjusted results are non-GAAP financial measures QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of its ongoing core operations, vary significantly from period to period, or affect the comparability of results with its competitors and its own prior periods. QIAGEN does not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGEN’s GAAP results.

Q1 2026: Overview

1. **Preliminary Q1 2026: Mixed net sales trends, adj. EPS achieving outlook**
   - $492 mn net sales (+2% actual, -1% CER vs. ≥1% CER outlook)
   - $0.54 CER adjusted diluted EPS in line with outlook

2. **Strong growth among key pillars, led by Sample technologies and QIAcuity**
   - Sample technologies: +9% CER growth, +3% CER growth excluding Parse
   - QIAcuity: Double-digit CER growth on instrument placements and consumables expansion
   - QDI: Solid single-digit growth

3. **QuantiFERON sales impacted by lower immigration testing demand**
   - -5% CER decline mainly due to sharply lower immigration testing (U.S./Middle East)
   - Solid trends in other key patient testing groups and key markets worldwide

4. **Ongoing solid profitability**
   - 27.4% adj. operating income margin
   - Absorbed about 3.4 ppts headwinds from tariffs, currency movements and acquisitions

5. **Updated FY 2026 outlook**
   - ~+1-2% CER net sales growth, led by ~+4% CER growth in H2 2026
   - ≥$2.43 CER adjusted diluted EPS



CER – Constant exchange rates

Q1 2026: Sales performance and key developments

Sales by product group

(In $ millions at actual rates)



Key developments

Sample technologies	• +9% CER growth, +3% CER growth excl. Parse • Parse integration progressing well, on track to exceed ~$40 mn FY 2026 sales target
QuantiFERON	• -5% CER decline amid sharp drop in immigration testing • Strong uptake of new high-throughput Diasorin chemistry
QIAstat-Dx	• -1% CER decline as expected vs. strong Q1 2025 • Consumables led by double-digit GI and Meningitis panel growth
QIAcuity	• Double-digit CER growth led by consumables and instruments • Continued adoption supported by all regions
QDI	• Solid single-digit CER growth driven by clinical double-digit growth • Advancing portfolio with AI-enhanced products

(1) Q1: Net sales $477 million CER (-1% at constant exchange rates, +2% at actual rates)
CER – Constant exchange rates

Q1 2026: Portfolio developments

Sample technologies – Parse:
Advancing scalable single-cell sequencing

Launch of Evercode® Whole Transcriptome chemistry

- Enables scalability of up to 5 million cells with improved sensitivity and cell recovery
- Simplified, automation-ready workflow with lower sequencing costs



Oncology portfolio:
Addressing key oncology research needs

Expansion of genomic profiling solutions in oncology

- **Genomics/NGS**: New QIAseq panels enabling broad genomic profiling
- **QDI**: Introduction of AI-grounding solution for unified drug discovery support in research

QIAstat-Dx:
Advancing syndromic testing solutions

Launch of new QIAstat-Dx panels and QIAstat-Dx Rise menu expansion

- Blood culture panel: Entry into bloodstream infection testing (Europe)
- GI panels: Menu expansion on QIAstat-Dx Rise (U.S.)

FY 2026 sales outlook: Updated perspectives



Updated FY 2026 sales outlook: ~+1-2% CER growth

CER – Constant exchange rates | ppts – Percentage points

FY 2026: Leveraging a solid portfolio to drive growth

	Sample tech	QuantiFERON	QIAcuity	QIAstat-Dx	QDI	Growth pillars total sales (CER)
						
2026 CER targets (February 2026)	~$720 mn	~$535 mn	~$100 mn	~$160 mn	~$125 mn	**~$1.64 bn**
Updated 2026 CER targets (April 2026)	~$720 mn	Updated ~$500 mn	~$100 mn	~$160 mn	~$125 mn	**~$1.61 bn** **~7% CER growth**

Q1 2026: 4 out of 5 pillars delivered or exceeded expectations

CER – Constant exchange rates

2026 sales outlook: H1 vs. H2 updated perspectives



Multiple levers to improve sales trends in H2 2026

CER – Constant exchange rates I ppts – Percentage points I (1) QIAstat-Dx and QIAcuity launches

Q2 and FY 2026: Updated outlook and assumptions

(As of April 27, 2026)	Q2 2026 outlook	FY 2026 outlook
Net sales	**~ -2% CER**	**~+1-2% CER**
Anticipated currency impact(1)	Positive impact of ~+1 ppt	Positive impact of ~+1 ppt
Adjusted diluted EPS(2)	**≥$0.60 CER**	**≥$2.43 CER**
Anticipated currency impact(1)	Neutral	Neutral
Adjustments to operating income (In $ millions):		
Business integration and acquisition-related items	~$8 mn	~$25 mn
Restructuring-related items	~$7 mn	~$45 mn
Amortization of acquired intellectual property	~$15 mn	~$62 mn
Adjusted tax rate (%)	**~17-18%**	**~17-18%**
Weighted average number of diluted shares outstanding (Based on $40.00 share price)	**~208 million**	**~209 million**

(1) Based on exchange rates as of April 27, 2026.

(2) QIAGEN reports adjusted results to provide additional insight into its performance. Adjusted results are non-GAAP financial measures that QIAGEN believes should be considered in addition to reported results prepared in accordance with GAAP but should not be considered as a substitute. QIAGEN believes certain items should be excluded from adjusted results when they are outside of ongoing core operations, vary significantly from period to period, or affect the comparability of results with competitors and its own prior periods. Furthermore, QIAGEN uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, as well as to measure and compensate employees. QIAGEN also uses adjusted results when comparing current performance to historical operating results, which have consistently been presented on an adjusted basis.

QIAGEN

Appendix

Q1 2026: Maintaining solid profitability while investing in future growth



ppts– Percentage points

Your contacts

Daniel Wendorff

Vice President
Head of Investor Relations

Phone: +49 2103 29 11322
E-mail: daniel.wendorff@qiagen.com

Dr. Domenica Martorana

Associate Director
Investor Relations

Phone: +49 2103 29 11244
E-mail: domenica.martorana@qiagen.com

Alexandra Koenig

Coordinator
Investor Relations

Phone: +49 2103 29 11709
E-mail: alexandra.koenig@qiagen.com

Calendar

Q1 2026 full results	May 6, 2026
QuantiFERON Spotlight Session	May 7, 2026
Annual General Meeting	June 2026
Q2 2026 results	August 2026

Share information

NYSE:	QGEN
Frankfurt:	QIA
ISIN / CUSIP:	NL0015002SN0 / N72482 156
WKN:	A41HBE

E-mail:
ir@qiagen.com

Internet:
corporate.QIAGEN.com

QGEN LISTED NYSE

DAX

TecDAX

www.linkedin.com/company/qiagen

www.x.com/QIAGEN

www.facebook.com/QIAGEN

www.youtube.com/user/QIAGENvideos